Security key
230031106
Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)
CUSIP: 230031106
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 63,192,288
- Total 13F value
- $653,889,874
- Share change
- +1,996,985
- Put/Call ratio
- 21%
- SEC-reported price per share
- $10.35
- Number of holders
- 153
- Value change
- +$34,298,477
- Number of buys
- 90
- Number of sells
- 58
- Shares outstanding
- 61,708,871
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
153
Top holders
10
CGEM full security history
Ownership snapshot
Full 13F holder table
Cullinan Therapeutics, Inc. SEC filings
Cullinan Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
15/15
Latest evidence
31 Dec 2025
3/4/5
13D/G
13F
Lead comparable stake: 14%
13D/G row: Lynx1 Capital Management LP
Showing 1-6 of 15 holder rows.
Quick read
Lynx1 Capital Management LP leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership
Top 5
Lynx1 Capital Management LP
14%
Kynam Capital Management, LP
5.3%
James E. Flynn
5%
FRANKLIN RESOURCES INC
3.8%
CITADEL ADVISORS LLC
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
14%
from 13D/G
|
$75,297,881
8,963,500 shares
|
+$13,322,539 | 28 Oct 2025 |
| Kynam Capital Management, LP |
13D/G
13F
Company
|
5.3%
|
$37,245,019
3,114,132 shares
|
$0 | 31 Dec 2025 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
5%
|
$17,357,187
2,927,013 shares
|
$0 | 30 Sep 2025 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
3.8%
|
$17,836,873
2,191,262 shares
|
$0 | 30 Sep 2024 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
3.4%
|
$11,794,219
1,988,907 shares
|
-$6,049,899 | 30 Sep 2025 |
| MPM BioImpact LLC |
13F
Company
|
12%
|
$45,354,229
7,648,268 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
153
Shares
63,192,288
Rows available
153
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
142
Q4 2025 holders
153
Holder diff
11
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|